ホーム › びまん性大細胞型B細胞リンパ腫 › オハイオ
オハイオにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
オハイオ内の拠点で、びまん性大細胞型B細胞リンパ腫に関する23件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Aultman Health Foundation, Canton
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06649812Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of Cincinnati Medical Center ( Site 0156), Cincinnati
- University Hospitals of Cleveland ( Site 0155), Cleveland
- Fairview Hospital-Moll Cancer Center ( Site 0198), Cleveland
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06091865A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002), Cincinnati
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- The Ohio State University (OSU), Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07225439Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Oncology Hematology Care - Kenwood, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT06536049Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
- Cleveland Clinical Taussig Cancer Center, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- The Ohio state University, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05077527Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Case Western Reserve University, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/09更新 · NCT06015880A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- University of Cincinnati, Cincinnati
- Ohio State University, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT04775745Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Case Western Reserve University, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05780034DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Toledo Clinic Cancer Center, Toledo
被験者募集中第2相
18歳以上 · 全性別 · 2023/04/07更新 · NCT04920617Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- University of Cincinnati, Cincinnati
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2022/08/04更新 · NCT04502394ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。